Exozymes Inc. (EXOZ) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
Net income was -$9.2M, or -$1.09 per diluted share. Operating activities generated -$6.5M of cash, leaving -$6.7M of free cash flow. At fiscal year end, Exozymes held $6.0M in total assets against $2.6M in total liabilities, including $3.0M of cash and equivalents.
Open the full interactive Exozymes financials → Quarterly statements, key ratios, valuation history and price charts.
Exozymes Key Stats
| Share Price | $4.59 |
|---|---|
| Market Cap | $39.8M |
| 52-Week Range | $4.40 – $16.50 |
| Shares Outstanding | 8.7 million (basic, 2026 Q2) |
Exozymes Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Operating Income | -$5.9M | -$9.7M |
| Pre-Tax Income | -$5.9M | -$9.3M |
| Income Tax | — | -$105,205 |
| Net Income | -$5.9M | -$9.2M |
| Diluted EPS | -$0.89 | -$1.09 |
Exozymes Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Net Income | -$2.3M | -$2.7M | -$2.4M | -$2.9M |
| Diluted EPS | -$0.27 | -$0.32 | -$0.28 | -$0.33 |
Exozymes Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $9.7M | $3.0M |
| Current Assets | $10.8M | $3.9M |
| Total Assets | $13.0M | $6.0M |
| Current Liabilities | $1.3M | $1.6M |
| Total Liabilities | $2.6M | $2.6M |
| Shareholders' Equity | $10.4M | $3.4M |
Exozymes Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$8.5M | -$6.5M |
| Cash From Investing | -$359,216 | -$150,218 |
| Cash From Financing | $18.5M | -$27,709 |
| Free Cash Flow | -$8.9M | -$6.7M |
Figures from Exozymes' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Exozymes financials page for every line item.
Exozymes Company Profile
| Ticker | EXOZ |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Monrovia, California |
| Incorporated in | Nevada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0002010788 |
Frequently Asked Questions
What was Exozymes' net income in fiscal 2025?
Exozymes reported net income of -$9.2M for fiscal 2025.
What was Exozymes' earnings per share (EPS) in fiscal 2025?
Exozymes' diluted EPS was -$1.09 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Exozymes generate in fiscal 2025?
Exozymes generated -$6.7M of free cash flow in fiscal 2025.
How many shares of Exozymes are outstanding?
Exozymes reported a weighted average of 8.7 million basic shares outstanding in 2026 Q2.
What is Exozymes' market cap?
Based on its latest closing price, Exozymes (EXOZ) has a market capitalization of about $39.8M.
When does Exozymes' fiscal year end?
Exozymes' fiscal year end, as registered with the SEC, is December 31.
Where is Exozymes headquartered?
Exozymes lists its business address in Monrovia, California in its SEC filings.